Relevance of dedicated multiple sclerosis serum biomarkers in predicting contrast enhancement with gadolinium - Results from the REDUCE-GAD trial.
Jan Hendrik SchaeferMartin A Schaller-PauleKatharina WengerChristoph MayerUlrike MannAlexander BickertFalk SteffenStefan BittnerYavor YalachkovChristian FoerchPublished in: European journal of neurology (2023)
Evaluation of several possible serum biomarkers for CE in MS patients provided the most robust results for NFL, particularly as Z-scores. Following further evaluation, biomarkers may help stratifying the application of contrast agents for brain imaging in MS patients.
Keyphrases
- multiple sclerosis
- end stage renal disease
- chronic kidney disease
- ejection fraction
- magnetic resonance
- mass spectrometry
- prognostic factors
- ms ms
- peritoneal dialysis
- randomized controlled trial
- patient reported outcomes
- study protocol
- contrast enhanced
- magnetic resonance imaging
- functional connectivity
- patient reported
- open label
- resting state
- computed tomography
- quantum dots